Worldwide Clinical Trials Appoints Global Head of Quality

Doyle will be responsible for safeguarding the company’s compliance and risk and ensuring the highest quality services as the company scales to deliver against record growth.

According to the Industry Standard Research (ISR) CRO Benchmarking Report, Worldwide is consistently rated as a top performer for quality by the company’s pharmaceutical and biotech customers.

“Quality assurance is the backbone of our company and is a differentiator for Worldwide,” said Peter Benton, president and chief operating officer, Worldwide Clinical Trials. “With his proven ability to manage quality and compliance through significant growth, I know Phillip is the right person to ensure that our customers continue to associate the Worldwide brand with world-class good clinical research practices and study integrity.”

Doyle last served as Senior Director, R&D Quality Assurance, for Sangamo Therapeutics. Prior to that, he held senior quality assurance leadership roles with BioMarin, Exelixis, Inc., Pharm-Olam, Corvax Solutions and Kinetic Concepts (now Acelity).

“The opportunity to apply my experience in life sciences R&D quality provides a new challenge – further developing the already excellent quality systems in place at Worldwide,” said Doyle. “Yet, quality has no finish line. I’m looking forward to helping Worldwide continuously improve and work to the highest standards as we aspire to be the world’s best midsized CRO.”

Doyle holds an LL.M in international and comparative law and a Juris Doctorate from St. Mary's University, a BA in business management from St. Mary’s College, and an AA in journalism from Gavilan College.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005228/en/